2019
DOI: 10.1038/s41586-019-1404-z
|View full text |Cite
|
Sign up to set email alerts
|

Neuronal vulnerability and multilineage diversity in multiple sclerosis

Abstract: Multiple sclerosis (MS) is a neuroinflammatory disease with a relapsing-remitting disease course at early stages, distinct lesion characteristics in cortical gray versus subcortical white matter, and neurodegeneration at chronic stages. We assessed multilineage cell expression changes using single-nucleus RNA sequencing (snRNA-seq) and validated results using multiplex in situ hybridization in MS lesions. We found selective vulnerability and loss of excitatory CUX2 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

44
518
3
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 400 publications
(573 citation statements)
references
References 53 publications
44
518
3
2
Order By: Relevance
“…Our analysis yielded 24,735 brain nuclei profiles and provide a resource to better understand the complex cellular interactions and gene expression profiles that may contribute to the pathogenesis of CTE. Similar to previous reports using snRNA-seq in other neurological diseases, including Alzheimer's disease (AD), multiple sclerosis (MS), autism spectrum disorder (ASD), and epilepsy (Mathys et al 2019;Grubman et al 2019;Jäkel et al 2019;Schirmer et al 2019;Velmeshev et al 2019), our findings indicate changes in cell types, subpopulations, and gene expression in CTE. Our findings are the first report of molecular and cellular changes at single nucleus resolution in CTE.…”
Section: Introductionsupporting
confidence: 90%
See 1 more Smart Citation
“…Our analysis yielded 24,735 brain nuclei profiles and provide a resource to better understand the complex cellular interactions and gene expression profiles that may contribute to the pathogenesis of CTE. Similar to previous reports using snRNA-seq in other neurological diseases, including Alzheimer's disease (AD), multiple sclerosis (MS), autism spectrum disorder (ASD), and epilepsy (Mathys et al 2019;Grubman et al 2019;Jäkel et al 2019;Schirmer et al 2019;Velmeshev et al 2019), our findings indicate changes in cell types, subpopulations, and gene expression in CTE. Our findings are the first report of molecular and cellular changes at single nucleus resolution in CTE.…”
Section: Introductionsupporting
confidence: 90%
“…To produce a robust tSNE for further analysis, we fine-tuned parameters over various iterations to identify clusters that appeared consistently (Kobak and Berens 2019;Jäkel et al 2019;Mathys et al 2019;Grubman et al 2019;Schirmer et al 2019;Velmeshev et al 2019). After comparing a variety of parameters, we chose 23 principal components and a resolution of 0.8 for input parameters ( Supplementary Fig.…”
Section: Cellular Diversity and Cell-type-specific Changes In Cte Whimentioning
confidence: 99%
“…To gain new insights into cell populations and cell type-specific differences in gene expression, evolution, neurogenic capability, and variable disease susceptibility, we performed high-coverage single-nucleus RNA sequencing (snRNA-seq) on five anatomically defined subregions of the hippocampal-entorhinal system. These efforts, like similar recent efforts to transcriptomically characterize the postmortem adult human brain (Krishnaswami et al, 2016; Lake et al, 2016; Habib et al, 2017; Lake et al, 2018; Li et al, 2018; Hodge et al, 2019; Mathys et al, 2019; Schirmer et al, 2019; Velmeshev et al, 2019) (including pioneering profiling of HIP (Habib et al, 2017), identified a highly diverse set of neuronal and non-neuronal cell types with clear regional distinctions and implications for human brain function, evolution, and disease.…”
Section: Introductionmentioning
confidence: 85%
“…Murine scRNA‐seq studies have advanced the characterization of OL‐lineage transcriptomic signatures, with several studies identifying intermediate states between progenitors and fully differentiated cells (Artegiani et al, ; Marques et al, ; reviewed in van Bruggen, Agirre, & Castelo‐Branco, ). Human tissue‐based studies that focus on OL‐lineage cells have applied sequencing of nuclei (snRNA‐seq) derived from postmortem tissues from adult “control” donors and individuals with clinical conditions that include MS (Jakel et al, ; Schirmer et al, ), Alzheimer's disease (Mathys et al, ), and autism (Velmeshev et al, ). However, studies of human OL‐lineage development remain limited by the availability of whole cell samples that would permit inclusion of non‐nuclear RNAs, and material that encompasses a wide age span including time of peak myelination.…”
Section: Introductionmentioning
confidence: 99%